Search clinical trials for: tagraxofusp

Total 14 results

University of Kansas Medical Center

Not yet recruiting

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis，MF
Sidney Kimmel Comprehensive Cancer Center at Johns...
StemlineTherapeutics, Inc.

Recruiting

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG)

Acute Myeloid Leukemia

United States
Therapeutic Advances in Childhood Leukemia Consortium

Recruiting

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Lymphoma, B-Cell | Hodgkin Lymphoma | Lymphoblastic Lymphoma | Lymphoma, T-Cell | AML | Hematologic Malignancy | MDS | Acute Undifferentiated Leukemia | ALL | Mixed Phenotype Acute Leukemia | BPDCN

United States, Australia
Joshua Zeidner
University of North Carolina, Chapel Hill; Stemline Therapeutics, Inc.

Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (TAGALONG)

Acute Myeloid Leukemia

United States
Karen Ballen, MD

Recruiting

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

Acute Myeloid Leukemia | Myelofibrosis | Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Acute Myeloid Leukemia

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Stemline Therapeutics, Inc.

Terminated

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Jonsson Comprehensive Cancer Center
Stemline Therapeutics, Inc.

Withdrawn

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Stemline Therapeutics, Inc.

Completed

Tagraxofusp (SL-401) in Patients With CMML or MF

Myelofibrosis | Chronic Myelomonocytic Leukemia

United States, Canada
Stemline Therapeutics, Inc.

Terminated

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Acute Myeloid Leukemia

United States

Search clinical trials for: tagraxofusp

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations